You searched for Small Lymphocytic Lymphoma - Page 4 of 55

ASH 2021: SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

February 16, 2022

This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients without the high-risk mutation,17p deletion [del(17p)].

The Genetics of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) in African Americans and Other Minorities

January 5, 2022

Sadly, there has been very little research on minority populations with chronic lymphocytic leukemia/small lymphocytic lymphoma. Dr. Slager in partnership with Dr. Esteban Braggio, Mayo Clinic, is hoping to start to remedy that knowledge gap with a trial specifically for minorities with CLL.

Real-World Testing Patterns for Risk Assessment and Implications on the Adoption of Novel Therapeutics in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL): IgHV Mutation Status, FISH Cytogenetic, and Immunophenotyping

January 5, 2022

As new and better treatments are developed to treat Chronic Lymphocytic Leukemia, and Small Lymphocytic Lymphoma (CLL / SLL), testing for subtypes of the disease is becoming more important for prognosis and selection of the best treatment options.

CAR-T Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) Made Easy to Understand

December 23, 2021

CAR-T therapy is a revolutionary therapy that trains the patient’s own cells to attack their CLL / SLL. The science can be somewhat complicated and advanced, but the results can be amazing. You

ASH 2020: Dr. Alexey Danilov on Inhibiting MCL1 to Overcome Resistance to Ibrutinib and Venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL / SLL and Other Non-Hodgkin’s Lymphoma or NHL

November 18, 2021

At the virtual American Society of Hematology Annual Meeting and Exposition or ASH 2020, Dr. Alexey Danilov of City of Hope was interviewed by CLL Society’s Steve Bloom on his important preclinical research to address one of the significant unmet needs in CLL / SLL/ patients: resistant to venetoclax and/or ibrutinib.

Why Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients Need Passive Immunity

November 5, 2021

CLL Society’s Executive VP and Chief Medical Officer (CMO), Dr. Brian Koffman has been busy over the last weeks trying to get the word out about the unique risks and needs of the CLL / SLL community on TV, news, and medical literature as listed below.

ASCO 2021 Top Pick #6: Fixed Duration (FD) First-Line Treatment with Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the FD Cohort of the Phase 2 CAPTIVATE Study

October 4, 2021

The CAPTIVATE study data has been highly anticipated. At ASH 2020, we got important results. Dr. Wierda presented the results of Minimal (Measurable) Residual Disease (MRD) cohort using MRD status to guide therapy: Undetectable MRD (uMRD) was achieved in >2/3 of patients with 12 cycles of I+V, and the 30 months progression free survival or PFS rates was an impressive ≥95%.

EHA 2021 Top Pick #4: First Interim Analysis of the ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

October 4, 2021

This was accepted as a late breaking abstract at the 2021 European Hematology Association Virtual Congress, (EHA 2021), reflecting its importance to the best management of relapsed/ refractory (R/R) chronic lymphocytic leukemia (CLL). Investigators from multiple CLL centers in Europe, Australia, and North America were involved in this research.

Understanding Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL / SLL)

August 31, 2021

Understanding Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL / SLL) In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Search Results for: Small Lymphocytic Lymphoma – Page 4

ASH 2021: SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine plus Rituximab (BR) in Patients with Treatment Naive (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

The Genetics of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) in African Americans and Other Minorities

Real-World Testing Patterns for Risk Assessment and Implications on the Adoption of Novel Therapeutics in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL): IgHV Mutation Status, FISH Cytogenetic, and Immunophenotyping

CAR-T Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) Made Easy to Understand

ASH 2020: Dr. Alexey Danilov on Inhibiting MCL1 to Overcome Resistance to Ibrutinib and Venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma or CLL / SLL and Other Non-Hodgkin’s Lymphoma or NHL

Why Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients Need Passive Immunity

ASCO 2021 Top Pick #6: Fixed Duration (FD) First-Line Treatment with Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Analysis of the FD Cohort of the Phase 2 CAPTIVATE Study

EHA 2021 Top Pick #4: First Interim Analysis of the ALPINE Study: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL)

Understanding Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL / SLL)

Didn't find what you where looking for?

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT